KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Minority Interest (2016 - 2025)

Teva Pharmaceutical Industries' Minority Interest history spans 17 years, with the latest figure at $4.0 million for Q3 2025.

  • For the quarter ending Q3 2025, Minority Interest fell 98.75% year-over-year to $4.0 million, compared with a TTM value of $4.0 million through Sep 2025, down 98.75%, and an annual FY2024 reading of $340.0 million, changed N/A over the prior year.
  • Minority Interest for Q3 2025 was $4.0 million at Teva Pharmaceutical Industries, down from $7.0 million in the prior quarter.
  • The five-year high for Minority Interest was $987.0 million in Q2 2021, with the low at $4.0 million in Q3 2025.
  • Average Minority Interest over 5 years is $605.4 million, with a median of $751.0 million recorded in 2022.
  • Year-over-year, Minority Interest rose 1.54% in 2021 and then tumbled 98.75% in 2025.
  • Tracing TEVA's Minority Interest over 5 years: stood at $966.0 million in 2021, then decreased by 17.81% to $794.0 million in 2022, then fell by 26.7% to $582.0 million in 2023, then crashed by 41.58% to $340.0 million in 2024, then tumbled by 98.82% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Minority Interest are $4.0 million (Q3 2025), $7.0 million (Q1 2025), and $340.0 million (Q4 2024).